Your Catalyst to a Lucrative Business
In 2016, Crohn’s disease was the largest indication segment for the visceral pain market contributing to
41.4% of the market share. Increasing occurrences of Crohn’s disease across the globe coupled with
the growing drug therapies for the treatment of the disease are the key factors attributing to the major
share. Furthermore, increasing awareness about Crohn’s disease is fueling the demand for treatment
therapies.
Key market players include Pfizer, Johnson & Johnson, Abbvie, Takeda, Allergan, and AstraZeneca.
These companies are focusing on R&D for visceral pain therapeutics. These companies are likely to
cater their products to patients affected by visceral pain. The growth of the geriatric population is
expected to help in augmenting the profits of these companies over the next few years.
Growing focus on research and development by pharmaceutical companies and government initiatives
are expected to boost the visceral pain industry during the forecast period. The market is projected to
witness significant gain during the forecast period owing to increasing collaboration within
pharmaceutical companies. Also, factors such as increasing awareness among people regarding
visceral pain are further anticipated to propel the market growth.
Hexa Research has segmented the global visceral pain market on the basis of therapeutics, indications
and region:
Segmentation by therapeutics, 2014 - 2024 (USD Million)
• Analgesics
• Narcotics
• NSAID
• Pain modifiers
• Tricyclic Antidepressants
• Tricyclic Anticonvulsant
• Others
Segmentation by indications, 2014 - 2024 (USD Million)
• Interstitial cystitis
• Crohn’s
• Irritable bowel
• Chronic prostatitis
Segmentation by region, 2014 - 2024 (USD Million)
• North America
• Europe
• Asia Pacific
• Rest of the World (RoW)
Key players analyzed:
• Pfizer Inc.
• Allergan
• Johnson & Johnson
Follow Us: